Transplantation for hilar cholangiocarcinoma

Julie K. Heimbach, Michael Haddock, Steven Robert Alberts, Scott Nyberg, Michael B. Ishitani, Charles B. Rosen, Gregory James Gores

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

1. Patients with primary sclerosing cholangitis(PSC) have a 8 to 12% risk of developing cholangiocarcinoma (CCA). 2. Cytologic techniques for aneuploidy such as digital image analysis and fluorescence in situ hybridization increase the detection rate for CCA. 3. Survival following resection for CCA is 20% to 40% at 5 years. 4. Survival following liver transplantation for unresectable, perihilar CCAs, mass lesion if present <3 cm, is greater than 80% at 5 years. 5. Patients with intrahepatic CCAs are not eligible for liver transplantation.

Original languageEnglish (US)
JournalLiver Transplantation
Volume10
Issue number10 SUPPL. 2
DOIs
StatePublished - Oct 2004

Fingerprint

Klatskin Tumor
Cholangiocarcinoma
Transplantation
Liver Transplantation
Sclerosing Cholangitis
Survival
Aneuploidy
Fluorescence In Situ Hybridization

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Transplantation for hilar cholangiocarcinoma. / Heimbach, Julie K.; Haddock, Michael; Alberts, Steven Robert; Nyberg, Scott; Ishitani, Michael B.; Rosen, Charles B.; Gores, Gregory James.

In: Liver Transplantation, Vol. 10, No. 10 SUPPL. 2, 10.2004.

Research output: Contribution to journalArticle

Heimbach, Julie K. ; Haddock, Michael ; Alberts, Steven Robert ; Nyberg, Scott ; Ishitani, Michael B. ; Rosen, Charles B. ; Gores, Gregory James. / Transplantation for hilar cholangiocarcinoma. In: Liver Transplantation. 2004 ; Vol. 10, No. 10 SUPPL. 2.
@article{2d9533c290c24306aed4ea076a782f3e,
title = "Transplantation for hilar cholangiocarcinoma",
abstract = "1. Patients with primary sclerosing cholangitis(PSC) have a 8 to 12{\%} risk of developing cholangiocarcinoma (CCA). 2. Cytologic techniques for aneuploidy such as digital image analysis and fluorescence in situ hybridization increase the detection rate for CCA. 3. Survival following resection for CCA is 20{\%} to 40{\%} at 5 years. 4. Survival following liver transplantation for unresectable, perihilar CCAs, mass lesion if present <3 cm, is greater than 80{\%} at 5 years. 5. Patients with intrahepatic CCAs are not eligible for liver transplantation.",
author = "Heimbach, {Julie K.} and Michael Haddock and Alberts, {Steven Robert} and Scott Nyberg and Ishitani, {Michael B.} and Rosen, {Charles B.} and Gores, {Gregory James}",
year = "2004",
month = "10",
doi = "10.1002/lt.20266",
language = "English (US)",
volume = "10",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "10 SUPPL. 2",

}

TY - JOUR

T1 - Transplantation for hilar cholangiocarcinoma

AU - Heimbach, Julie K.

AU - Haddock, Michael

AU - Alberts, Steven Robert

AU - Nyberg, Scott

AU - Ishitani, Michael B.

AU - Rosen, Charles B.

AU - Gores, Gregory James

PY - 2004/10

Y1 - 2004/10

N2 - 1. Patients with primary sclerosing cholangitis(PSC) have a 8 to 12% risk of developing cholangiocarcinoma (CCA). 2. Cytologic techniques for aneuploidy such as digital image analysis and fluorescence in situ hybridization increase the detection rate for CCA. 3. Survival following resection for CCA is 20% to 40% at 5 years. 4. Survival following liver transplantation for unresectable, perihilar CCAs, mass lesion if present <3 cm, is greater than 80% at 5 years. 5. Patients with intrahepatic CCAs are not eligible for liver transplantation.

AB - 1. Patients with primary sclerosing cholangitis(PSC) have a 8 to 12% risk of developing cholangiocarcinoma (CCA). 2. Cytologic techniques for aneuploidy such as digital image analysis and fluorescence in situ hybridization increase the detection rate for CCA. 3. Survival following resection for CCA is 20% to 40% at 5 years. 4. Survival following liver transplantation for unresectable, perihilar CCAs, mass lesion if present <3 cm, is greater than 80% at 5 years. 5. Patients with intrahepatic CCAs are not eligible for liver transplantation.

UR - http://www.scopus.com/inward/record.url?scp=6944252082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6944252082&partnerID=8YFLogxK

U2 - 10.1002/lt.20266

DO - 10.1002/lt.20266

M3 - Article

C2 - 15382214

AN - SCOPUS:6944252082

VL - 10

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 10 SUPPL. 2

ER -